Our executive team is comprised of dedicated and diligent personnel.

Interim CEO, Chairman & Director

Evripides (Roy) Drakos

Mr. Evripides Roy Drakos has over twenty five years of experience in satellite communications and a dozen years involved in special projects in the field of pioneering technology and marketing strategies accumulating unique skills and knowledge authority in the industry.

Mr. Drakos is an inspirational leader, a technology inventor, investment advisor, and market development strategist. During his services in the last three decades, he has accumulated unique experience through his involvement in technology pioneering and financial engineering in emerging markets, medical science, renewable energy and hi-tech patent investments. He has also acted as the principal advisor for private equity investments and boutique family offices. Mr. Drakos also supports the satellite communication industry, as his principal activity, focusing on strategy and business development in emerging markets for blue chip satellite communication companies. He also offers investment advise for Inter-M Traders Group of Companies for patented technologies in medical science and renewable energy. Motivated through his passion to serve the unserved around the world, Mr Drakos accumulated a global network of associates and business leaders actively sharing the same values and vision. As an inspirational leader and investment advisor he is well recognized for his ability to create great value for the investors and deliver expansion strategies for high-end pioneering networks and solutions.
Director, Head of Science

Dr. Peter Whitton

Dr. Whitton has wide ranging expertise, having provided advisory services to leading pharmaceutical companies such as GlaxoSmithKline and Boots on regulatory strategy, as well as directing research and providing toxicology advice to Pfizer.

Dr. Peter Whitton is a well-respected expert in the fields of microbiology and biochemistry with over 20 years’ experience in his field, and is recognized as a leader in the field of plant cell culturing and research. Dr. Whitton has a BSC in Biology with Chemistry and a PhD in Biochemistry. He is a member of the Institute of Biology and a chartered biologist, a member of the Royal Society of Chemistry and a Fellow of the Institute of Biomedical Sciences. Dr. Whitton has wide ranging expertise, having provided advisory services to leading pharmaceutical companies such as GlaxoSmithKline and Boots on regulatory strategy, as well as directing research and providing toxicology advice to Pfizer. Dr. Whitton previously served as director and Chief Scientific Officer for Naturally Scientific Technologies Ltd., where he developed and patented methods for the production of glyceraldehyde from CO2 and the production of Lipids using plant cell culture technologies. Prior to joining Naturally Scientific Dr. Whitton ran and managed his own research organization, Phyto-Research Ltd., for five years and secured a number of patents in the field of plant tissue cultures and natural sciences, as well as providing research and advisory services to leading pharmaceutical companies and universities. During this period Dr. Whitton worked with The Serious and Organized Crime Directorate of the Metropolitan Police with Assistant Commissioner Tarique Gaffur on the development of new drug and explosive detection techniques. Dr. Whitton held the position of senior scientist for a number of years for an organization specializing in the preparation of herbal-based remedies and cosmetics and was responsible for research, quality and conformance with British Pharmacopeia Standards and compliance with Cosmetic Safety regulations. Dr. Whitton has successfully patented many bio-technology patents with a particular focus on the use of plant cell technology for industrial applications. Dr. Whitton was a co-founder and currently services as a director of Lykke Research Ltd., a bio-technology company that has developed and patented a process to produce the API from the Hoodia Gordonii plant from cell cultures for use in the dietary supplements market as an appetite suppressant. He is the co-founder and a director of PhytoCyte Pty, a bio-technology company that has developed a process to produce cannaboids and their API’s from cell cultures for the medicinal and recreational cannabis markets.
Executive Vice President, Secretary, & Director

Aristotle Popolizio

Mr. Popolizio leads a team in research, raising capital and the development of operational risk management plans, and ensures the company is appropriately and strategically positioned with analysts, investors, and all stakeholders.

Aristotle Popolizio is the head of Investment Relations at Inter-M Traders Ltd., a family office equity investment fund, with offices in Cyprus and New York City. Mr. Popolizio leads a team in research, raising capital and the development of operational risk management plans, and ensures the company is appropriately and strategically positioned with analysts, investors, and all stakeholders. Mr. Popolizio has a BS in Risk Management and a Minor in International Business from the Smeal college of The Pennsylvania State University. Mr. Popolizio provides advisory services in a wide variety of sectors, including pharmaceutical companies, bio-medical companies, CPA’s, attorneys, and government bodies. Mr. Popolizio holds licenses with FINRA (series 7 and series 66) and NIPR (life insurance, accident and health insurance, property insurance, and casualty insurance).
Director

Sagi Rozen

Mr. Rozen also specialises in corporate legal disputes, finance law, international corporate governance and commercial law. With a proven track record and firm standards of professionalism, trustworthiness and client service he focuses on increasing Companies Value and Presence in the Various Markets.

Mr. Sagi Rozen is an Israeli Lawyer, Partner in the Israel Law Firm ‘David Rozen Law Firm’ with presence in Israel and Cyprus.

Fearless with a strategic mindset, Mr Rozen is dealing globally with international High Net Worth Clients providing the best results with specialisation in the USA Market, Raising Capital, Tax Planning, Corporate Structures, Merges and Acquisitions , global banking solutions and investments in the Capital Markets.

Mr. Rozen also specialises in corporate legal disputes, finance law, international corporate governance and commercial law.

With a proven track record and firm standards of professionalism, trustworthiness and client service he focuses on increasing Companies Value and Presence in the Various Markets.

Areas of expertise include venture capital raising and managing complex legal cases in order to create an effective and promising solution for clients' capital.

Don't wait any longer to capitalize on plant cell replication.

Learn more about how we believe our innovative process will leave traditional methods out to dry. Opportunities are available now.

For investor inquiries:
For partner inquiries: